trending Market Intelligence /marketintelligence/en/news-insights/trending/4jP1g6qbHUxyeuYtVAxS1A2 content esgSubNav
In This List

Millendo Therapeutics prices $25M offering to fund product candidates

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Millendo Therapeutics prices $25M offering to fund product candidates

Millendo Therapeutics Inc. priced its offering of 4,166,667 common shares at $6 each.

The Ann Arbor, Mich.-based biopharmaceutical company granted underwriters a 30-day option to buy up to an additional 625,000 common shares at the same price.

Gross proceeds are expected to be about $25 million.

The offering is expected to close Dec. 9. Proceeds will be used to develop product candidates in its pipeline and for working capital, capital expenditures and general corporate purposes.

Citigroup and SVB Leerink are acting as joint book-running managers for the offer.

Millendo Therapeutics develops medicines for orphan endocrine diseases.